Navigation Links
New Treatment Boosts Survival Chances for Child Leukaemia

A prototype method of treating infants with a form of leukaemia boosts their chances of survival compared with the standard drug regimen, according to a paper published in next Saturday's Lancet.

In general, children with acute lymphoblastic leukaemia have a good chance of survival -- about 80 percent today, compared with only 10 percent 40 years ago.

But this success rate drops significantly in infants aged under 12 months, where it falls to a range of 17-45 percent.

Dutch doctors carried out a study of 482 infants from 22 countries who were aged under one year and had been diagnosed with the disease.

In addition to the standard drug for acute lymphoblastic leukaemia -- a treatment called Prednisone -- the children were given tiny doses of drugs usually designed for treating a related form of cancer, acute myeloid leukaemia.

The key ingredient was Cytabarine, which in lab-dish tests have been shown to be highly effective against lymphoblasts, as immature lymphocyte cells are called.

At the 38-month followup mark, 260 (58 percent) of the patients who received this "hybrid" treatment were in complete remission.

Meanwhile, a separate study, also published in The Lancet, highlights new combination chemotherapy for chronic lymphyocytic leukaemia, the commonest form of leukaemia in the developed world.

Institute of Cancer Research doctors in Britain found that fludarabine (marketed as Fludara) and chlorambucil (Leukeran), when used together, were no better than fludarabine alone or chorambucil alone in boosting a patient's chance of survival five years after treatment.

However, the combination more than tripled the chance that the disease had not progressed by the time of the five-year checkup.


Page: 1

Related medicine news :

1. Advances in Treatment of Cataracts
2. Recommendations for Treatment of Blood Pressue
3. Treatment for Menieres disease
4. Treatment for pre-menstrual syndrome is ineffective
5. Better Treatment for obesity
6. Gene Treatment for Heart Disease
7. More People Seeking Treatment for Depression
8. Focused Treatment For Childhood Cancer
9. Inadequate Drug Treatment For Youth
10. FDA Approves New surgery Treatment for Farsightedness
11. Treatment of antibiotics ineffectual in bronchitis
Post Your Comments:

(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... products to meet the demand of today’s consumer and regulatory authorities worldwide. From ... probiotic experts and tested to meet the highest standard. , These products ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
(Date:10/12/2017)... ... , ... On Saturday, October 21, the Health & Wellness Center at Florida ... money for the American Heart Association Heart Walk. Teams of up to 10 people ... keep their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... Oct. 12, 2017 AVACEN Medical , Inc. ... with their  2017 New Product Innovation Award for Its ... primary and secondary medical device market research by Frost & ... first-to-market OTC, drug-free pain relief product, the AVACEN 100, offers ... treating fibromyalgia widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE MKT: ... that developed an innovative way to use nonlinear optical ... delivery of new drugs. ... Dermatology Conference will show how researchers from BioPharmX and ... Medical School used a suite of imaging techniques in ...
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
Breaking Medicine Technology: